About Cantargia

Company Description

Cantargia is a Swedish biotechnology company that specializes in the development of pharmaceuticals for various types of cancer and inflammatory/autoimmune diseases. Our development programme includes the candidate drugs nadunolimab (CAN04), currently in phase IIa clinical studies, and CAN10, currently in preclinical phase, as well as our discovery project CANxx. The company is listed on OMX Stockholm’s Main List (Mid Cap).

Cantargia AB was founded in 2009-2010 with the aim of refining a discovery by Professor Thoas Fioretos and Doctor Marcus Järås of Lund University. Their research showed that leukemic stem cells express a protein on their surface – IL1RAP – that is not expressed to as great a degree on normal stem cells. Further research demonstrated that this protein is also found on cancer cells from a large number of solid tumor types.

Year founded

2009

Headquarters

Scheelevägen 27, 22363 Lund – Sweden

Shareholder information

Shares outstanding

166,987,895

IPO

Jan. 1, 2000

Stock exchange(s)

Nasdaq Stockholm

Contact

Newsletter

Subscribe to our newsletter and receive information about recent IPOs, news in the European capital market and more.